Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin

Four models of acquired resistance to the clinically-used platinum drug, oxaliplatin, have been established using human tumour cell lines in vitro; two colon (HCT116 and HT29) and two ovarian (A2780 and CH1). Levels of acquired resistance ranged from 3.0- to 15.8-fold with levels of resistance highe...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of cancer (1990) Vol. 38; no. 17; pp. 2309 - 2315
Main Authors:	Sharp, S.Y, O'Neill, C.F, Rogers, P, Boxall, F.E, Kelland, L.R
Format:	Journal Article
Language:	English
Published:	Oxford Elsevier Ltd 01.11.2002 Elsevier
Subjects:	Antineoplastic agents Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Biological and medical sciences Cell Division Chemotherapy Circumvention Colonic Neoplasms - drug therapy Colonic Neoplasms - metabolism Colonic Neoplasms - pathology DNA, Neoplasm - metabolism Drug Resistance, Neoplasm Female Humans Male Medical sciences Mismatch repair Organoplatinum Compounds - pharmacokinetics Organoplatinum Compounds - therapeutic use Ovarian Neoplasms - drug therapy Ovarian Neoplasms - metabolism Ovarian Neoplasms - pathology Oxaliplatin Pharmacology. Drug treatments Resistance Tumor Cells, Cultured ZD0473 Resistance ZD0473 Oxaliplatin Circumvention Mismatch repair Antineoplastic agent Human Cell proliferation Cell culture Treatment resistance Carcinoma Acquired Malignant tumor In vitro Female genital diseases Colonic disease Ovarian diseases Ovary Chemotherapy Established cell line Digestive diseases Colon Molecular biology Platinum II Complexes
ISSN:	0959-8049, 1879-0852
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!